Company Filing History:
Years Active: 2018
Title: Delphine Chen: Advancements in Cancer Imaging
Introduction
Delphine Chen, an innovative scientist based in Brentwood, Missouri, has made significant strides in the field of cancer imaging. Her work primarily focuses on the development of radiolabeled tracers that enhance the ability to visualize specific biological processes, particularly through positron emission tomography (PET) imaging.
Latest Patents
Chen holds a noteworthy patent titled "Radiolabeled tracers for poly (ADP-ribose) polymerase-1 (PARP-1), methods and uses therefor." This patent involves the synthesis of PARP-1 inhibitors that can be fluorine-18 labeled to be utilized as tracers in PET imaging. Among the synthesized compounds, 2-[p-(2-Fluoroethoxy)phenyl]-1.3.10-triazatricyclo[6.4.1.0]trideca-2,4(13),5,7-tetraen-9-one (12) demonstrated the highest inhibition potency for PARP-1 with an IC of 6.3 nM. The synthesis of [F]-12 is notable for its progression under conventional conditions, achieving high specific activity and a decay-corrected yield of 40-50%. MicroPET imaging in MDA-MB-436 tumor-bearing mice showcased the significant accumulation of [F]-12 within the tumor, demonstrating the compound's potential in tumor imaging applications.
Career Highlights
Delphine Chen is currently affiliated with Washington University, a prestigious institution known for its research contributions. Her role involves ongoing research in the synthesis and application of innovative imaging technologies to better understand and visualize cancerous tissues. Her patent is a testament to her expertise and commitment to advancing the medical field through targeted imaging techniques.
Collaborations
Throughout her career, Chen has collaborated with esteemed colleagues, including Robert H. Mach and Wenhua Chu. These collaborations have played a critical role in her research endeavors, fostering a shared knowledge environment that enhances the development of new imaging modalities and therapeutic strategies.
Conclusion
Delphine Chen represents a remarkable force in the realm of cancer research and imaging. Her patent on radiolabeled tracers highlights her contributions to the scientific community while opening new avenues for effective tumor imaging. As she continues her research at Washington University, her innovations are likely to have a profound impact on the future of cancer diagnostics and treatment.